Zc3h13, a zinc-finger protein, is an important regulator in the m6A methylation machinery. N6-methyladenosine (m6A) is a prevalent modification in eukaryotic mRNA, influencing mRNA stability, splicing, export, and translation. Zc3h13 is part of the "writers" group of m6A regulators, which install m6A modifications. It plays a crucial role in multiple biological processes and is associated with various diseases, highlighting its overall biological importance [1,3].

Knockdown of Zc3h13 in mouse embryonic stem cells significantly decreases global m6A levels on mRNA. It is required for the nuclear localization of the Zc3h13-WTAP-Virilizer-Hakai complex, which is essential for RNA m6A methylation. Depletion of Zc3h13 impairs self-renewal and triggers mESC differentiation [1]. In cervical cancer, Zc3h13-mediated m6A modification of CENPK mRNA promotes cancer stemness and chemoresistance [2]. In papillary thyroid carcinoma, overexpressed Zc3h13 suppresses tumor growth through m6A modification-mediated IQGAP1 degradation [4]. In laryngeal squamous cell carcinoma, Zc3h13 reduces DUOX1-mediated ferroptosis through m6A-dependent modification [5]. In colorectal cancer, Zc3h13 acts as a tumor suppressor, inactivating the Ras-ERK signaling pathway [6]. In keloid formation, Zc3h13 accelerates the process by mediating the m6A modification of HIPK2 [7]. In acute myocardial infarction, ZC3H13-mediated m6A modification ameliorates the condition by preventing inflammation, oxidative stress, and ferroptosis [8].

In conclusion, Zc3h13 is essential for m6A methylation in the nucleus, regulating processes like embryonic stem cell self-renewal. Its role in various disease conditions such as cancer and cardiac diseases has been revealed through model-based research, especially gene-knockout studies. Understanding Zc3h13's functions provides insights into disease mechanisms and potential therapeutic targets for these diseases.